Telitacicept

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Adults with IgA nephropathy (conditional approval) (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Latest reported trial: NCT05737160 · Phase 3 · met primary endpoint · grade pending

Also in development:Rheumatoid Arthritis · Phase 3 · investigational in the USSjögren's Disease · Phase 3 · investigational in the US · under NMPA reviewIgA Nephropathy · Phase 3 · investigational in the US

Also approved (5)
CN
  • Adults with IgA nephropathy (conditional approval)biospace.com
  • Adults with Sjögren's diseasebiospace.com
  • Adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis, in combination with conventional therapiesfinance.yahoo.com
  • Rheumatoid arthritisremegen.com
  • Systemic lupus erythematosus (conditional approval; later converted to full approval)biospace.com
Product first approved 2021

Development in Systemic Lupus Erythematosus stopped (2025-01) as a strategic decision by the sponsor. Source

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (16)
Generalized Myasthenia Gravis
NCT06456580 · Vor Biopharma
2024-07-17 – 2029-01 · Generalized Myasthenia Gravis
What this study did
IgA Nephropathy
NCT07052981 · Guixia Ding
2025-08-01 – 2027-06-30 · IgA Nephropathy (IgAN), IgAVN
What this study did
NCT07098897 · The Affiliated Hospital of Xuzhou Medical University
2024-08-01 – 2025-09-30 · IgA Nephropathy (IgAN)
What this study did
Rheumatoid Arthritis
Sjögren's Disease
NCT07404865 · Vor Biopharma
2026-02-26 – 2029-01 · Primary Sjogren's Disease
What this study did
Other / comorbidity
NCT07495033 · RemeGen Co., Ltd.
2026-04-20 – 2030-05-31 · CTD-ILD
What this study did
NCT06125405 · The Children's Hospital of Zhejiang University School of Medicine
2023-11-28 – 2027-10-24 · Nephrotic Syndrome in Children, Telitacicept
What this study did
NCT07249632 · RemeGen Co., Ltd.
2026-01-13 – 2027-02-28 · Myasthenia Gravis, Ocular
What this study did
NCT03330418 · RemeGen Co., Ltd.
2018-01-29 – 2026-04-03 · Neuromyelitis Optica Spectrum Disorders
What this study did
NCT05339217 · Liu Tian
2023-02-07 – 2025-07-01 · Systemic Lupus Erythematosus
What this study did
NCT06456567 · Vor Biopharma
2024-09 – 2025-01-06 · Systemic Lupus Erythematosus
What this study did
NCT05306574 · Vor Biopharma
2022-06-20 – 2025-01-06 · Systemic Lupus Erythematosus
What this study did
Phase 2/3 (2)
IgA Nephropathy
NCT05596708 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2023-03-01 – 2026-09-30 · IgA Nephropathy
What this study did
Other / comorbidity
NCT07355257 · Zhongming Qiu
2026-02-02 – 2027-03-30 · Inflammatory Myopathy
What this study did
Phase 2 (21)
IgA Nephropathy
NCT07522099 · ADARx Pharmaceuticals, Inc.
2026-05-21 – 2029-01-21 · Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN
What this study did
NCT04905212 · RemeGen Co., Ltd.
2021-11-04 – 2023-11-09 · IgA Nephropathy
What this study did
NCT04291781 · RemeGen Co., Ltd.
2020-04-13 – 2021-05-20 · Primary IgA Nephropathy
What this study did
Rheumatoid Arthritis
NCT07796516 · Peking University People's Hospital
2026-09-01 – 2028-06-30 · Difficult-to-treat Rheumatoid Arthritis, Rheumatoid Arthritis
What this study did
Sjögren's Disease
NCT07836660 · Innovent Biologics (Suzhou) Co. Ltd.
2026-10-15 – 2028-10-31 · Sjögren's Disease
What this study did
NCT04078386 · RemeGen Co., Ltd.
2019-11-21 – 2021-10-26 · Primary Sjögren's Syndrome
What this study did
Other / comorbidity
NCT07340463 · Nanjing University School of Medicine
2025-12-08 – 2029-06 · Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
What this study did
NCT07902609 · First Affiliated Hospital, Sun Yat-Sen University
2026-06-20 – 2028-06-30 · Antibody-mediated Rejection, Antibody-Mediated Rejection (AMR)
What this study did
NCT06375005 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-01-06 – 2027-12-31 · Diffuse Cutaneous Systemic Sclerosis
What this study did
NCT07687134 · Institute of Hematology & Blood Diseases Hospital, China
2026-07-10 – 2027-12-31 · Immune Thrombocytopenia
What this study did
NCT06614985 · Renmin Hospital of Wuhan University
2024-10-20 – 2027-10-01 · Primary Membranous Nephropathy
What this study did
NCT07111338 · Peking University First Hospital
2025-07-12 – 2027-05-29 · Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits
What this study did
NCT04625153 · RemeGen Co., Ltd.
2021-05-13 – 2026-04-03 · Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT06315530 · Ruijin Hospital
2023-12-01 – 2026-01-06 · Antiphospholipid Syndrome (APS)
What this study did
NCT05680480 · RemeGen Co., Ltd.
2023-04-17 – 2026-01 · Lupus Nephritis
What this study did
NCT05998759 · Beijing Hospital
2023-12-02 – 2025-12 · Connective Tissue Diseases, Thrombocytopenia
What this study did
NCT05078710 · Peking Union Medical College Hospital
2021-07-01 – 2025-06-01 · Anti Phospholipid Syndrome
What this study did
NCT05929248 · Guanmin Gao
2023-07-01 – 2024-12-30 · Systemic Lupus Erythematosus
What this study did
NCT02885610 · RemeGen Co., Ltd.
2015-12 – 2019-07-09 · Systemic Lupus Erythematosus
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT06656962 · Renmin Hospital of Wuhan University
2024-10-10 – 2026-10-30 · Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN)
What this study did
Phase 1 (5)
IgA Nephropathy
NCT07886476 · Innovent Biologics (Suzhou) Co. Ltd.
2026-10-15 – 2028-02-28 · IgA Nephropathy (IgAN)
What this study did
Other / comorbidity
NCT05687526 · RemeGen Co., Ltd.
2023-05-25 – 2025-11-14 · Systemic Lupus Erythematosus
What this study did
NCT05247203 · RemeGen Co., Ltd.
2022-05-11 – 2023-11-13 · Systemic Lupus Erythematosus
What this study did
NCT04235933 · RemeGen Co., Ltd.
2019-09-17 – 2019-12-20 · Healthy
What this study did
Phase 4 (9)
Rheumatoid Arthritis
NCT07008196 · Chinese SLE Treatment And Research Group
2025-06-10 – 2026-01 · Rheumatoid Arthritis (RA)
What this study did
Other / comorbidity
NCT06677801 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2024-10-11 – 2027-10-31 · Systemic Lupus Erythematosus (SLE)
What this study did
NCT07077486 · Tongji Hospital
2025-08-25 – 2027-03-25 · Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus
What this study did
NCT05965284 · Chinese SLE Treatment And Research Group
2023-03-09 – 2026-12-31 · ANCA-associated Vasculitis, Maintenance Therapy
What this study did
NCT05962840 · Chinese SLE Treatment And Research Group
2023-06-29 – 2026-12-31 · ANCA Associated Vasculitis
What this study did
NCT06723548 · First Affiliated Hospital of Wenzhou Medical University
2024-12 – 2026-12 · Myasthenia Gravis, Autoimmune Diseases
What this study did
NCT06546540 · Peking University Third Hospital
2024-06-08 – 2026-03-30 · Systemic Sclerosis
What this study did
NCT05899907 · Peking Union Medical College Hospital
2022-09-01 – 2025-09-01 · Lupus Erythematosus, Systemic
What this study did
NCT05666336 · Fen Li
2022-12-31 – 2024-06-30 · Systemic Lupus Erythematosus
What this study did
Early phase / not applicable (5)
Generalized Myasthenia Gravis
NCT06827587 · First Affiliated Hospital of Wenzhou Medical University
2025-02 – 2026-12 · Myasthenia Gravis, Autoimmune Diseases, Neuromuscular Diseases
What this study did
IgA Nephropathy
NCT06654596 · Ruijin Hospital
2024-12-06 – 2026-12 · IgA Nephropathy (IgAN), Kidney Diseases, Telitacicept, Glucocorticoid
What this study did
Other / comorbidity
NCT07298928 · The Children's Hospital of Zhejiang University School of Medicine
2026-03-10 – 2028-12 · Effectiveness
What this study did
NCT07597733 · Sichuan Academy of Medical Sciences
2025-09-26 – 2027-08-31 · Refractory Chronic Inflammatory Demyelinating Polyneuropathy
What this study did
NCT06394063 · RenJi Hospital
2024-06-28 – 2027-06-30 · Systemic Lupus Erythematosus
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Generalized Myasthenia Gravis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Telitacicept: this drugPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
Eculizumab (Soliris)ApprovedMonoclonal antibodyComplement C5Partial signal
NCT01997229: Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Eculizumab 56.6 scores on a scale (Standard Error 4.53) | Placebo 68.3 scores on a scale (Standard Error 4.49) missed
Efgartigimod Alfa (Vyvgart)ApprovedAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
Efgartigimod Alfa And Hyaluronidase (Vyvgart Hytrulo)ApprovedAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
InebilizumabApprovedMonoclonal antibodyCD19Reliable signal
NCT04524273: Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population (Baseline and Week 26): Overall: Placebo -2.2 Score on a scale (95% CI -3 to -1.5) | Overall: Inebilizumab 300 mg -4.2 Score on a scale (95% CI -4.9 to -3.4)
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
CemdisiranPhase 3RNA / oligonucleotideComplement C5not yet gradedNo reviewed efficacy summary in this indication
Gefurulimab (Klygefa)Phase 3Antibody-derived scaffoldComplement C5not yet gradedNo reviewed efficacy summary in this indication
Iptacopan (Fabhalta)Phase 3Small moleculeComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
Pozelimab (Veopoz)Phase 3Monoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
AritinerceptPhase 1/2Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(19 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Telitacicept to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
December 2026 (4)
Early phase / not applicableIgA NephropathyRecruiting
Est. primary completion 2026-12 · NCT06654596 · CT.gov ↗
What to watch
Phase 2/3Inflammatory MyopathyNot yet recruiting
Est. primary completion 2026-12-30 · NCT07355257 · CT.gov ↗
What to watch
Phase 3Myasthenia Gravis, OcularRecruiting
Est. primary completion 2026-12-31 · NCT07249632 · CT.gov ↗
What to watch
Phase 4ANCA Associated VasculitisRecruiting
Est. primary completion 2026-12-31 · NCT05962840 · CT.gov ↗
What to watch
2027 (11)
January 2027 (2)
Phase 2Diffuse Cutaneous Systemic SclerosisRecruiting
Est. primary completion 2027-01-06 · NCT06375005 · CT.gov ↗
What to watch
Phase 1IgA NephropathyNot yet recruiting
Est. primary completion 2027-01-31 · NCT07886476 · CT.gov ↗
What to watch
March 2027 (1)
Phase 3Generalized Myasthenia GravisActive not recruiting
Est. primary completion 2027-03 · NCT06456580 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Proliferative Glomerulonephritis With Monoclonal Immunoglobulin DepositsActive not recruiting
Est. primary completion 2027-05-29 · NCT07111338 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2Systemic Lupus ErythematosusRecruitingDiscontinued in this indication
Est. primary completion 2027-06 · NCT07340463 · CT.gov ↗
What to watch
Phase 3IgA NephropathyNot yet recruiting
Est. primary completion 2027-06-30 · NCT07052981 · CT.gov ↗
What to watch
Early phase / not applicableSystemic Lupus ErythematosusRecruitingDiscontinued in this indication
Est. primary completion 2027-06-30 · NCT06394063 · CT.gov ↗
What to watch
August 2027 (1)
Early phase / not applicableRefractory Chronic Inflammatory Demyelinating PolyneuropathyActive not recruiting
Est. primary completion 2027-08-31 · NCT07597733 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Sjögren's DiseaseNot yet recruiting
Est. primary completion 2027-11-01 · NCT07836660 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Rheumatoid ArthritisRecruiting
Est. primary completion 2027-12-30 · NCT07796516 · CT.gov ↗
What to watch
Phase 2Antibody-mediated Rejection, Antibody-Mediated Rejection (AMR)Active not recruiting
Est. primary completion 2027-12-31 · NCT07902609 · CT.gov ↗
What to watch
2028 (3)
July 2028 (1)
Phase 2IgA NephropathyRecruiting
Est. primary completion 2028-07-10 · NCT07522099 · CT.gov ↗
What to watch
December 2028 (2)
Phase 3Sjögren's DiseaseRecruiting
Est. primary completion 2028-12 · NCT07404865 · CT.gov ↗
What to watch
Early phase / not applicableEffectivenessNot yet recruiting
Est. primary completion 2028-12 · NCT07298928 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
Phase 3CTD-ILDNot yet recruiting
Est. primary completion 2029-05-31 · NCT07495033 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 October 2025Topline resultPhase III Sjögren's Syndrome trial meets primary endpoint
19 September 2025Filing acceptedChina BLA for Sjögren's Syndrome accepted by CDE
CN, NMPA · Source ↗
13 August 2025Topline resultChina Phase 3 in primary Sjögren's (NCT05673993) met its primary endpoint
RemeGen Co., Ltd · Source ↗
27 May 2025ApprovalTelitacicept approved in China for generalized myasthenia gravis
CN, NMPA · Source ↗
8 April 2025Topline resultChina Phase 3 in generalized myasthenia gravis (NCT05737160): MG-ADL change -5.74 vs -0.91 with placebo at Week 24
RemeGen Co., Ltd · Source ↗